Previous Close | 0.7168 |
Open | 0.7399 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.7100 - 0.7399 |
52 Week Range | 0.3800 - 1.1500 |
Volume | |
Avg. Volume | 34,330 |
Market Cap | 26.07M |
Beta (5Y Monthly) | 1.65 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.0000 |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.88 |
DALLAS, March 18, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update.
DALLAS, December 01, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
DALLAS, November 13, 2023--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2023 results and provided a business update.